Molecular landscape of metastatic bronchial neuroendocrine tumors
Endocrine Connections · 2026-11-01 · 15 (11)
DOI: 10.1530/ec-26-0369 ↗Abstract
Abstract Objective Metastatic bronchial neuroendocrine tumors (MBNETs) are rare and poorly characterized. Understanding their molecular landscape is crucial. This pilot study aimed to identify key genetic and epigenetic alterations in MBNETs using large-scale genomic analyses to uncover potential therapeutic targets. Design and methods Ten patients diagnosed with MBNETs and treated at Institut Curie between 2016 and 2021 were included after providing consent. Targeted DNA sequencing, RNAseq, and methylation profiling were conducted on formalin-fixed paraffin-embedded (FFPE) and frozen metastatic tissues. Data were analyzed using bioinformatics pipelines to assess genetic mutations, transcriptional alterations, and methylation patterns. Results Mutations in epigenetic regulator genes, including MEN1 (20%), ARID1A (20%), KMT2B (10%), and KMT2C (10%), were identified, along with additional mutations in MGA (30%) and EIF1AX (20%). Transcriptomic analysis revealed significant differential expression of neuroendocrine-related genes (SSTR1, SSTR2, CHGA, and CHGB) in epigenetic regulator mutated tumors, showing an association with neuroendocrine phenotype regulation. Gene set enrichment analysis highlighted upregulation of neuroactive ligand–receptor interaction and cytokine signaling pathways. Methylation analysis showed distinct clustering of MEN1-mutated tumors, with differential methylation in various cancer genes, including IKBKE, WNT3A, MYOD1, DNMT3A, and ZNRF3. Conclusion Our pilot study highlights an association between epigenetic alterations and molecular features of MBNETs, with potential therapeutic implications that warrant further investigation. The higher expression of somatostatin receptors and neuroendocrine markers observed in tumors harboring epigenetic alterations provides a potential rationale for further investigation of targeted therapies. Further research is needed to explore the role of epigenetic modifications in MBNET progression and treatment response. Significance statement Metastatic bronchial neuroendocrine tumors (MBNETs) are rare and lack effective targeted therapies. This pilot study integrates genomic, transcriptomic, and epigenetic profiling of MBNETs, revealing frequent mutations in epigenetic regulators. These alterations correlate with distinct gene expression and methylation patterns, particularly involving somatostatin receptors and neuroendocrine markers. These findings suggest an association between epigenetic alterations and distinct molecular features of MBNETs and may guide future investigations of epigenetic drugs and receptor-targeted therapies. This work expands our understanding of MBNET biology and provides a rationale for precision medicine approaches in these aggressive tumors.
EUVIMED